Candidiasis, Oral Clinical Trial
Official title:
CelAgace™ OraRinse (CAOR) Pilot Clinical Study for Management of Candidiasis Associated With Grade 0-II Mucositis
CelAgace™ OraRinse (silver citrate complex and acemannan) Solution is planned to be evaluated for safety and effectiveness as a potential treatment for candidiasis, a yeast infection, commonly known as thrush, which is associated with mouth sores.
CelAgace™ contains two active ingredients, a silver citrate complex salt (0.01mg/ml) that has demonstrated laboratory effectiveness against yeast organisms and acemannan (4.0mg/ml), a purified extract isolated from the inner leaf gel of the Aloe vera plant that has been used as a key ingredient in other oral care products. Patients will swish and spit the product 4 times daily (after meals and at bedtime) for 14 days. Following an initial office visit, patients will be evaluated on days 7 and 14 to determine response to the product. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00004781 -
Oral Manifestations of Human Immunodeficiency Virus Infection in High Risk Groups
|
N/A | |
| Completed |
NCT03894839 -
Evaluation of the Effect of Different Cleaning and Disinfection Procedures on the Involvement of Candida Species
|
N/A | |
| Completed |
NCT00128323 -
A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis
|
Phase 3 | |
| Recruiting |
NCT04410250 -
Effect of Oral Hygienization in Newborn on Candida Spp Colonization
|
N/A | |
| Completed |
NCT02184351 -
Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis
|
Phase 3 | |
| Recruiting |
NCT03873753 -
Relationship Between Oral Hygiene in Newborns and Candida Spp.
|
N/A | |
| Completed |
NCT00665639 -
Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis
|
Phase 3 | |
| Completed |
NCT02818803 -
Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic
|
Phase 3 | |
| Active, not recruiting |
NCT06120816 -
Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis
|
Phase 1 | |
| Completed |
NCT00235053 -
Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID
|
Phase 4 | |
| Completed |
NCT00666185 -
Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis
|
Phase 3 | |
| Completed |
NCT00002446 -
Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
|
Phase 3 | |
| Completed |
NCT00001448 -
The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection
|
N/A | |
| Completed |
NCT00612963 -
Novel Rinse to Treat in Oral Candidiasis in Cancer Patients
|
N/A | |
| Completed |
NCT00001812 -
A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2
|
Phase 3 | |
| Terminated |
NCT00005920 -
Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole
|
Phase 2 | |
| Completed |
NCT00002431 -
The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients
|
N/A | |
| Completed |
NCT00002057 -
Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC
|
N/A | |
| Completed |
NCT00002394 -
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
|
N/A | |
| Completed |
NCT00002112 -
Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome
|
N/A |